Literature DB >> 35845259

Development of the CogDrisk tool to assess risk factors for dementia.

Kaarin J Anstey1,2,3, Scherazad Kootar1,2,3, Md Hamidul Huque1,2,3, Ranmalee Eramudugolla1,2,3, Ruth Peters1,2,3.   

Abstract

Introduction: We aimed to develop a comprehensive risk assessment tool for Alzheimer's disease (AD), vascular dementia (VaD), and any dementia, that will be applicable in high and low resource settings. Method: Risk factors which can easily be assessed in most settings, and their effect sizes, were identified from an umbrella review, or estimated using meta-analysis where new data were available.
Results: Seventeen risk/protective factors met criteria for the algorithm to estimate risk for any dementia including age, sex, education, hypertension, midlife obesity, midlife high cholesterol, diabetes, insufficient physical activity, depression, traumatic brain injury, atrial fibrillation, smoking, social engagement, cognitive engagement, fish consumption (diet), stroke, and insomnia. A version for AD excluded atrial fibrillation and insomnia due to insufficient evidence and included pesticide exposure. There was insufficient evidence for a VaD risk score. Discussion: Validation of the tool on external datasets is planned. The assessment tool will assist with implementing risk reduction guidelines.
© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  assessment; dementia; development; questionnaire; risk and protective factors; tool

Year:  2022        PMID: 35845259      PMCID: PMC9275658          DOI: 10.1002/dad2.12336

Source DB:  PubMed          Journal:  Alzheimers Dement (Amst)        ISSN: 2352-8729


INTRODUCTION

Clinicians, policy makers, and researchers need reliable and valid tools to assess risk factors for dementia, to implement brain health programs, and evaluate population‐level dementia risk. However, authorities differ in their proposed list of risk factors. The World Health Organization (WHO) guidelines did not find sufficient evidence to recommend interventions for hearing loss or social engagement, but did include recommendations related to diet, whereas the Lancet Commission recommended addressing hearing loss in midlife but did not make dietary recommendations. These differences reflect variations in methodologies and sources of data (i.e., clinical trials vs. observational studies). There is no individual cohort study or data source that includes all the risk factors that have been identified for dementia, and none that reflects global ethnic diversity. It is therefore likely that compared to risk tools developed on a single population, tools that are developed from meta‐analyses of the extant literature will provide a more reliable and generalizable assessment, in addition to allowing for inclusion of a larger number of risk factors.

Purpose of the present study

We developed a new risk assessment tool for dementia and Alzheimer's disease (AD) for use by clinicians, researchers, policy makers, and the general public, with the purpose of identifying risk factors and monitoring risk reduction efforts in high and low resource settings. First, we developed numerical risk scores for AD, any dementia and vascular dementia (VaD) using an evidence‐based medicine approach that draws on publications from observational studies. Due to limited data on VaD we did not proceed with a risk score for this. Second, we developed a tool to assess the risk factors included in the risk score. The final tool, called Assessment for Cognitive Health and Dementia Risk Reduction or “CogDrisk”, comprises the questionnaire and scoring algorithms.

METHODS

Selection of risk/protective factors for potential inclusion in the risk tool

We conducted a comprehensive systematic review of meta‐analyses from observational studies and identified 33 potential risk and protective factors for dementia and its subtypes. Criteria for inclusion of risk factors in the assessment tool included: systematic review‐level evidence reporting risk ratios (RRs) for the risk factors for dementia outcomes; risk factors must be assessable in a wide range of settings; and pharmacological risk factors with consistent supportive evidence from both cohort studies and clinical trials. , Recent reports were also considered. ,

Selection and computation of risk ratios for individual risk factors

Risk ratios were drawn from our umbrella review where possible. Measures of the risk factors, age group, number and recency of studies, and inclusion and exclusion criteria were evaluated before selecting effect sizes. Effect sizes available by age group and sex were preferentially selected. Risk/protective factors with a single effect size were selected if there was only one systematic review and the individual studies from the meta‐analysis could not be further categorized into mid/late‐life or by sex. In cases in which multiple systematic reviews conducted meta‐analysis of the same risk factor, the RR was recalculated by pooling the odds ratios/hazard ratios/relative RRs from the original cohort studies using the StatsDirect software (see supporting information for details).

Defining risk factors and selection of items for inclusion in assessment tool

Evidence‐based definitions of risk factors were used (e.g., the WHO guidelines for body mass index categories), and validated clinical cutoffs (e.g., Kivipelto and Solomon ). A questionnaire was collated using self‐reported items from the same scales as used in the original cohort studies from which RRs were drawn, where possible. Otherwise, a validated instrument was used (Table SA1 in supporting information).

RESEARCH IN CONTEXT

Systematic review: Implementation of brain health programs requires clear guidance on risk factors for dementia that can be validly assessed in low resource settings across different populations. Although there are at least three dementia risk assessments translated into tools, a significant amount of evidence has been published since they were developed. We drew evidence from recent reviews and meta‐analyses for dementia and major subtypes to identify risk factors with sufficient evidence to include in a low‐cost risk assessment tool. Interpretation: We identified 13 risk factors for any dementia, and 11 factors for Alzheimer's disease (AD), that had consistent evidence from reviews, included risk ratios (RRs), and were validly assessed via self‐report. The RRs were used to develop a scoring algorithm, and risk assessment tools (Assessment for Cognitive Health and Dementia Risk Reduction [CogDrisk] and CogDrisk‐AD) were developed using validated instruments or questions drawn from the original reports. Future directions: Validation of the CogDrisk on five external cohort studies across different populations is under way.

RESULTS

Number of risk factors selected for each outcome

Figure 1 depicts the steps involved in identifying risk factors for any dementia and shows that of 26 factors identified in the initial review, 13 met criteria for inclusion in the CogDrisk tool for any dementia. We further added two risk factors to the risk score for any dementia (i.e., hypertension and stroke) that were not identified in the initial review as well as age and sex, making a total of 17 risk factors (Figure 1, Table 1). Table 1 shows the risk factors and the RRs for the outcome of any dementia that are used in the CogDrisk tool.
FIGURE 1

Flowchart for selecting risk/protective factors for any dementia. AD, Alzheimer's disease; RR, risk ratio

TABLE 1

Risk factor categories and risk ratios for any dementia

Risk/protective factor, source of effect size Measure and categories Effect size (relative risk ratios) Beta weight Points
Age and sex 9
Age for males
60–64 yearsReference
65–69 years1.246
70–74 years1.958
75–79 years2.6213
80–84 years3.4017
85–89 years3.9220
>90 years4.4222
Age for females
60–64 yearsReference
65–69 years0.724
70–74 years1.397
75–79 years2.1911
80–84 years2.9815
85–89 years3.7419
>90 years4.5323
Education 13 Number of years   
Highest category (>11 years)ReferenceReference 
Highest vs. middle (8–11 years)1.52 (0.92–2.50)0.422
Highest vs. lowest (<8 years)2.23 (1.43–3.50)0.84
Midlife obesity (< = 65 years) 4 , a BMI categorized according to WHO guidelines
Normal (18.5–24.9)ReferenceReference
Overweight (25–29.9)1.34 (1.08–1.66)0.291
Underweight (<18.5)1.36 (1.07–1.73)0.312
Obese (≥30)1.72 (1.45–2.04)0.543
High cholesterol (<60 years) a Cholesterol <6.5 mmol/literReferenceReference 
Cholesterol >6.5 mmol/liter1.71(1.39–2.11) b 0.543
Diabetes 4 , a History of diabetes   
 No diabetesReferenceReference 
 Diabetes (males)1.61(1.42–1.83)0.482
 Diabetes (females)1.68 (1.64–1.71)0.523
Stroke 4 , a Stroke diagnosis based on ICD   
 No strokeReferenceReference 
 History of stroke (yes)1.60 (1.22–2.09) b 0.472
TBI 4 History of TBI (with and without loss of consciousness)   
 No prior TBIReferenceReference 
 Prior TBI1.63 (1.33–2.00)0.492
Hypertension (>65 years) 4 All combined high SBP, DBP, and hypertension1.31 (1.01–1.07) b 0.271
Atrial fibrillation (>65 years) 4 , a History of atrial fibrillation   
No atrial fibrillationReferenceReference 
Atrial fibrillation without stroke1.42 (1.17–1.72)0.492
Insomnia 4 Clinical diagnosis of insomnia   
 No insomniaReferenceReference 
 Insomnia1.53 (1.07–2.18)0.432
Depression 4 Centre for Epidemiological Studies Depression (CES‐D) scale   
 No depression (CES‐D < = 20)ReferenceReference 
 Depression (CES‐D > 20)1.98 (1.50–2.63)0.683
Physical inactivity 4 International guidelines for physical activity   
 InactiveReferenceReference 
 Physically active measured as >150 min/week of moderate to vigorous activity0.60 (0.51–0.71) b −0.51−3
Cognitive engagement 13 LowestReferenceReference 
 Middle0.43 (0.33–0.56)−0.97−5
 Highest0.38 (0.24–0.59)−0.84−4
Social engagement 4 Loneliness   
 Not lonelyReferenceReference 
 Lonely1.58 (1.19, 2.09)0.462
Diet 4 Fish, 1 serving/week   
 Less than 1 serving fish/weekReferenceReference 
 1 serving/week0.95 (0.90–0.99)−0.05−0.25
Smoking 4 Never smokedReferenceReference 
 Current smoker1.30 (1.18–1.45)0.261
 Former smoker1.01 (0.96–1.06)00

Effect sizes recalculated, see supporting information for details.

Effect size for AD was also used for any dementia due to classification of exposures being most relevant for risk assessment (e.g., for physical activity the effect size is for adherence to national guidelines whereas for any dementia the available effect size was for “high” and hence not translatable). Hypertension and stroke are other examples where despite the lack of clear effect sizes for any dementia in the review, there is strong evidence in the literature. , This might indicate that existing meta‐analyses may not capture all the relevant literature available highlighting the need to add these risk factors to the risk model.

Abbreviations: AD, Alzheimer's disease; BMI, body mass index; DBP, diastolic blood pressure; ICD, International Classification of Diseases; SBP, systolic blood pressure; TBI, traumatic brain injury; WHO, World Health Organization.

Flowchart for selecting risk/protective factors for any dementia. AD, Alzheimer's disease; RR, risk ratio Risk factor categories and risk ratios for any dementia Effect sizes recalculated, see supporting information for details. Effect size for AD was also used for any dementia due to classification of exposures being most relevant for risk assessment (e.g., for physical activity the effect size is for adherence to national guidelines whereas for any dementia the available effect size was for “high” and hence not translatable). Hypertension and stroke are other examples where despite the lack of clear effect sizes for any dementia in the review, there is strong evidence in the literature. , This might indicate that existing meta‐analyses may not capture all the relevant literature available highlighting the need to add these risk factors to the risk model. Abbreviations: AD, Alzheimer's disease; BMI, body mass index; DBP, diastolic blood pressure; ICD, International Classification of Diseases; SBP, systolic blood pressure; TBI, traumatic brain injury; WHO, World Health Organization. Results for AD are shown in supporting infomation (Figure SA1 and Table SA1). Of the 33 risk factors for AD, 13 met criteria for inclusion in CogDrisk tool for AD (CogDrisk‐AD). We further added one risk factor of social engagement to the list of risk factors for AD, and age and sex, making a total of 16. Figure SA2 in supporting information shows that of the eight risk factors identified for VaD, only four were suitable for inclusion in a tool. Table SA2 in supporting information shows the risk factors included in the CogDrisk compared to risk factors included in the Australian National University's Alzheimer's Disease Risk Index (ANU‐ADRI); Cardiovascular Risk Factors, Aging, and Dementia (CAIDE); and Lifestyle for Brain Health (LIBRA) tools. The main differences between the CogDrisk tool and CogDrisk‐AD are the omission of atrial fibrillation and insomnia from CogDrisk‐AD due to insufficient evidence that they increase the risk of AD, and the inclusion of pesticide exposure in CogDrisk‐AD. The sex‐based weights are also slightly different because of the higher risk of AD among women. A copy of the questionnaire is included in supporting information.

Construction of the risk algorithm and risk score

Risk algorithms were developed for any dementia to allow for the computation of risk scores for individuals (supporting information Part B). RRs were converted to points that were added to form a risk score. Conditional equations were specified for risk factors that only had an effect in midlife (high cholesterol, obesity and overweight). Sex was included as a conditional factor where RRs were available for males and females. Sex‐specific beta coefficients of age were estimated using recent global prevalence estimates. The final risk factors and weights for inclusion in the risk algorithm are shown in Table 1. A similar process was followed for AD (see Figure SA1 and Table SA1). The CogDrisk dementia score ranges from –4.25 to 45 for late‐life adults and from –8.25 to 28 for midlife adults, with a higher score indicating higher risk. A constant will be added to bring the range from 0 to 49.25 for late‐life adults and 0 to 36.52 for midlife adults. The weights for risk factors for AD are included in supporting information. The CogDrisk‐AD ranges from –3.4 to 43 for late‐life adults and from –8.4 to 26 for midlife adults. After adding a constant, that is 0 to 46.4 for late‐life adults and 0 to 34.4 for midlife adults.

Creation of the CogDrisk assessment tool

The CogDrisk assessment tool includes ≈90 questions and takes 30 to 40 minutes to complete (see supporting information).

DISCUSSION

To our knowledge, CogDrisk includes the largest number of modifiable risk factors for dementia of any existing dementia risk tool, and it also incorporates age group and sex differences. A more comprehensive assessment has greater capacity to identify risk factors relevant to more individuals, enabling preventive advice to be given for a larger group. The actual questionnaire includes items for both AD and any dementia to provide options for use in research or clinical settings. The weights associated with risk factors can also be used in population‐level research to estimate population‐attributable risk using administrative and registry data. Prior risk assessment tools include fewer risk factors: the CAIDE score assesses 7 risk factors, the LIBRA index assesses 11, and the ANU‐ADRI assesses 15. CogDrisk incorporates all the risk factors included in CAIDE and LIBRA except for coronary heart disease and renal dysfunction, which is only included in the LIBRA scale. In addition, the CogDrisk for any dementia includes social engagement and traumatic brain injury, which have only previously been included in the ANU‐ADRI. Importantly, the CogDrisk tool includes stroke and atrial fibrillation, which have not been included in any previous tool. The LIBRA tool does not include age, sex, or education because it focuses solely on modifiable risk factors. Some authors have argued that a limitation of risk tools is that age and sex account for a large proportion of the predictive power. However, risk reduction advice and interventions differ by age so retention of these variables is useful for developing preventive advice and programs. A limitation of CogDrisk is the length of the assessment. This is somewhat compensated by the design, which allows for the assessment without involvement of blood or imaging measures. Strengths include the evidence underpinning CogDrisk's development, the inclusion of age‐ and sex‐specific weights for some factors, and that it can be used in low‐resource settings. Future work already in progress will assess the validity of CogDrisk on five external cohort studies from the United States and Sweden that include many of the risk factors. Its predictive accuracy with and without age and sex, and its correlation with biomarkers, will also be examined.

CONFLICTS OF INTEREST

K.J.A. received a speaker honorarium from Nutricia in 2021. There are no other conflicts of interest. SUPPORTING INFORMATION Click here for additional data file. SUPPORTING INFORMATION Click here for additional data file.
  12 in total

1.  Lifestyle for Brain Health (LIBRA): a new model for dementia prevention.

Authors:  Olga J G Schiepers; Sebastian Köhler; Kay Deckers; Kate Irving; Catherine A O'Donnell; Marjan van den Akker; Frans R J Verhey; Stephanie J B Vos; Marjolein E de Vugt; Martin P J van Boxtel
Journal:  Int J Geriatr Psychiatry       Date:  2017-02-28       Impact factor: 3.485

2.  Stroke and dementia risk: A systematic review and meta-analysis.

Authors:  Elżbieta Kuźma; Ilianna Lourida; Sarah F Moore; Deborah A Levine; Obioha C Ukoumunne; David J Llewellyn
Journal:  Alzheimers Dement       Date:  2018-08-31       Impact factor: 21.566

Review 3.  Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence.

Authors:  M Kivipelto; A Solomon
Journal:  Acta Neurol Scand Suppl       Date:  2006

4.  Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years.

Authors:  Erik Joas; Kristoffer Bäckman; Deborah Gustafson; Svante Ostling; Margda Waern; Xinxin Guo; Ingmar Skoog
Journal:  Hypertension       Date:  2012-02-13       Impact factor: 10.190

5.  The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?

Authors:  Ruth Peters; Hiroko H Dodge; Sarah James; Gregory A Jicha; Pierre-Francois Meyer; Marcus Richards; A David Smith; Hussein N Yassine; Erin Abner; Atticus H Hainsworth; Patrick G Kehoe; Nigel Beckett; Craig S Anderson; Kaarin J Anstey
Journal:  Alzheimers Dement       Date:  2021-11-02       Impact factor: 21.566

Review 6.  Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.

Authors:  Ruth Peters; John Breitner; Sarah James; Gregory A Jicha; Pierre-Francois Meyer; Marcus Richards; A David Smith; Hussein N Yassine; Erin Abner; Atticus H Hainsworth; Patrick G Kehoe; Nigel Beckett; Christopher Weber; Craig Anderson; Kaarin J Anstey; Hiroko H Dodge
Journal:  Alzheimers Dement (N Y)       Date:  2021-12-08

Review 7.  Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention.

Authors:  Kaarin J Anstey; Nicolas Cherbuin; Pushpani M Herath
Journal:  Prev Sci       Date:  2013-08

8.  Developing points-based risk-scoring systems in the presence of competing risks.

Authors:  Peter C Austin; Douglas S Lee; Ralph B D'Agostino; Jason P Fine
Journal:  Stat Med       Date:  2016-05-19       Impact factor: 2.373

Review 9.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

Authors:  Gill Livingston; Jonathan Huntley; Andrew Sommerlad; David Ames; Clive Ballard; Sube Banerjee; Carol Brayne; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Sergi G Costafreda; Amit Dias; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Mika Kivimäki; Eric B Larson; Adesola Ogunniyi; Vasiliki Orgeta; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam
Journal:  Lancet       Date:  2020-07-30       Impact factor: 79.321

10.  Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models.

Authors:  Blossom C M Stephan; Eduwin Pakpahan; Mario Siervo; Silvan Licher; Graciela Muniz-Terrera; Devi Mohan; Daisy Acosta; Guillermina Rodriguez Pichardo; Ana Luisa Sosa; Isaac Acosta; Juan J Llibre-Rodriguez; Martin Prince; Louise Robinson; Matthew Prina
Journal:  Lancet Glob Health       Date:  2020-04       Impact factor: 38.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.